Feedback
BD Club Max
Login ×
Placeholder

BD at The Union World Conference on Lung Health

Paris

Add to fav remove to fav Add to favorites Thumb up remove thumb up Like the content

Thanks to all who joined us at The Union World Conference on Lung Health. The BD team was happy to be among the 3,781 attendees from across the globe in Paris, France, 15-18th November, 2023.

Through seminars, workshops and discussions with other congress attendees at our booth, we shared experiences and learned more about the latest in tuberculosis (TB). We were also happy to discuss the BD TB diagnostics portfolio, including solutions for detecting Mycobacterium TB (MTB) and potential resistance, such as the BD MAX™ System and BD BACTEC™ MGIT™ 320/960 for automated rapid detection of Mycobacteria.

Some of the key topics during the event included:

  • Increasing access to new treatment regimens, like BPal (Bedaquiline, Pretomanid and Linezolid)
  • New diagnostic tools for TB drug susceptibility testing
  • Latest treatment research on multidrug-resistant TB (MDR-TB)
  • Next Generation Sequencing (NGS) and Whole Genome Screening (WGS) technologies for TB

Watch the video we shared during the event:

To add to the discussion on TB treatment, our team was able to share the news around the new BD Bedaquiline Standardised Antimicrobial Reagent. We hope to help reduce the number of MDR-TB cases by enabling more accurate treatment with the introduction of this new treatment solution.
Learn more about the new BD Bedaquiline Standardised Antimicrobial Reagent and the full BD portfolio of antimicrobial reagents in lyophilised format:

DISCOVER OUR ANTIMICROBIAL REAGENT PORTFOLIO

We were also excited to share more about the BD MAX™ MDR-TB Assay and its recent endorsement by the World Health Organisation (WHO).
Learn more about BD MAX™ MDR-TB Assay:

READ THE STUDY

We are proud to share these recent achievements with a community that shares our diagnostic vision. Every new innovation is a step toward achieving higher diagnostic standards for TB.
Learn more about BD TB solutions:

LEARN MORE

If you want to stay up to date on the latest in TB, follow the link below:

STAY UP TO DATE

Thank you for taking the journey with us at The Union World Conference on Lung Health. We hope to see you again soon!

The BD MAX™ System, the BD BACTEC™ MGIT™ 320, BD BACTEC™ MGIT™ 960 and the BD MAX™ MDR-TB Assay are in vitro diagnostic medical devices bearing a CE mark.

Registration closed

Paris
2023-11-15

How can BD MAX™ Club support your lab’s challenges?

All topics

Why join BD MAX™ Club?

Connect with professionals from around the world BD MAX™ Club members represent a community of professionals in infectious diseases and molecular diagnostics. With regional meet-ups and live webinars from global experts, expand your laboratory’s network and collaborate with worldwide colleagues.

Tailored medical and technical expertise Whether you need compelling scientific research or tutorials for troubleshooting on the BD MAX™ System, BD MAX™ Club is here to accompany your molecular diagnostics journey. Log in to your BD MAX™ Club account anywhere, anytime to access our information database.

Exclusive members’ perks BD MAX™ Club membership unlocks doors to exclusive webinars and collaboration with industry leading experts. Engage with your colleagues in the molecular community and exchange with the BD research and development team.

Join BD MAX™ Club

Forward Looking Statement

The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures.

All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.